Abstract Number: 2043 • ACR Convergence 2020
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…Abstract Number: 0861 • ACR Convergence 2020
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…Abstract Number: 0460 • ACR Convergence 2020
Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
Background/Purpose: Anterior uveitis is a form of ocular inflammation associated with rheumatologic disease and can be categorized as granulomatous or non-granulomatous. Whether different ocular manifestations…Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…Abstract Number: 0462 • ACR Convergence 2020
Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer…Abstract Number: 0947 • ACR Convergence 2020
STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease
Background/Purpose: cGAS-STING is a cytosolic dsDNA sensing pathway whose regulation is vital to immune homeostasis. Pediatric patients with constitutively active STING mutations develop an autoinflammatory…Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…Abstract Number: 0463 • ACR Convergence 2020
Molecular Diagnosis of Childhood Immunodysregulation, Endocrinopathy and Enteropathy X-linked (IPEX)-Like Syndrome and Implications for Clinical Management
Background/Purpose: Patients with early-onset immunodysregulation, endocrinopathy and enteropathy but without identified mutations in FOXP3 are termed “IPEX-like,” and undergo trial-and-error immunosuppressive treatment with highly variable…Abstract Number: 1208 • ACR Convergence 2020
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: Novel subcutaneous infliximab (CT-P13 SC) was developed to augment the flexibility in the therapeutic use of infliximab and non-inferiority (NI) of CT-P13 SC versus…Abstract Number: 1578 • ACR Convergence 2020
Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing
Background/Purpose: Infusion-related reactions have been reported with rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, and may result in discontinuation of the…Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…Abstract Number: 1255 • ACR Convergence 2020
Sjӧgren’s Syndrome Minor Salivary Gland Mesenchymal Stromal Cells Derived Deploy Intact Immune Plasticity and Display Myofibroblast-Like Properties
Background/Purpose: Primary Sjӧgren’s syndrome (pSS) is the second most common systemic autoimmune disease with hallmark features of severe ocular and oral sicca, leading to reduced…
ACR Meeting Abstracts